AnaptysBio Inc

AnaptysBio Inc

ANAB

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.72B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
AnaptysBio IncAnaptysBio Inc-74.3--210%7.921.8
$73.38

Target Price by Analysts

15.7% upsideAnaptysBio Target Price DetailsTarget Price
$-14.56

Current Fair Value

123% downside

Overvalued by 123% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.72 Billion
Enterprise Value$2.75 Billion
Dividend Yield$- (-)
Earnings per Share$-0.46
Beta0.41
Outstanding Shares28,691,000

Return

Return on Equity-210.14%ROE
Return on Assets-8.13%
Return on Invested Capital10.96%

Valuation & Multiples

P/E Ratio-74.29P/E Ratio
PEG-215.56PEG
Price to Sales7.93Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue11.84
Enterprise Value to EBIT87.2
Enterprise Value to Net Income-103
Total Debt to Enterprise0.1
Debt to Equity21.76Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 12, 2026
EPS Estimate
$-0.32
Average shareholder expectation
Revenue Estimate
$18.86 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$-0.13
Average shareholder expectation
Revenue Estimate
$20.22 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.2151 131.78%
Total Calls25,100 91.26%
Total Puts5,400 98.77%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %152.41% 51.41%
Total Invested$1.55B 8.97%
Investors Holding210 26.00%

ESG Score

No data

About AnaptysBio Inc

CEO: Hamza Suria